New pill targets Alzheimer's in High-Risk gene carriers
NCT ID NCT04693520
First seen Jan 10, 2026 · Last updated May 01, 2026 · Updated 18 times
Summary
This study tested an oral drug called ALZ-801 in 84 people with early Alzheimer's who carry the APOE4 gene variant, which raises risk. The goal was to see if the drug affects key Alzheimer's-related proteins in the blood and brain, and to check its safety. Participants took the drug for 65 weeks, and researchers measured changes in biomarkers like p-tau181 and brain volume.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brain Research Center
's-Hertogenbosch, Netherlands
-
Brain Research Center
Amsterdam, Netherlands
-
Brain Research Center
Zwolle, Netherlands
-
Motol University Hospital
Prague, Czechia
-
St. Anne's University Hospital
Brno, Czechia
-
Vestra Clinics
Rychnov nad Kněžnou, Czechia
Conditions
Explore the condition pages connected to this study.